Ocular Inflammatory Complications of Treatment for Metastatic Melanoma.

Purpose: To characterize various ocular inflammatory complications arising from metastatic cutaneous melanoma therapies and their management.
Methods: Retrospective case series of patients who were referred to a tertiary uveitis practice for ophthalmic exam All patients received targeted metastatic cutaneous melanoma treatment, including BRAF/MEK inhibitors and various immunotherapies.
Results: 109 patients were identified, with 43 (39.4%) having 65 definitive instances of OIAE. Sixteen different OIAE were identified. Ipilimumab monotherapy and ipilimumab/nivolumab combination therapy were most commonly associated. Anterior uveitis was the most common OIAE (18/65, 27.7%). Thirty patients (69.8%) were managed with observation or topical steroid therapy. Only 4 patients required further therapies for OIAE, with one patient not attaining resolution.
Conclusions and Relevance: While a broad range of OIAE was identified, most were not vision-threatening and did not require discontinuation of the associated therapy.